Trial document





This study has been imported from ClinicalTrials.gov without additional data checks.
drksid header

  DRKS00004109

Trial Description

start of 1:1-Block title

Title

A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

[---]*

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

The primary objective of the phase III study is to investigate whether IMA901 can prolong
overall survival in patients with metastatic and/or locally advanced renal cell carcinoma
(RCC) when added to standard first-line therapy with sunitinib.

Secondary objectives include a subgroup analysis of overall survival in patients defined by
a certain biomarker signature, the investigation of progression-free survival, best tumor
response, safety, and immunological parameters.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

This is a multicenter, open-label, randomized phase III study to investigate whether
therapeutic vaccination with IMA901, a mult-peptide cancer vaccine (TUMAP), can prolong
overall survival in patients with metastatic and/or locally advanced RCC when added to
standard first-line therapy with sunitinib (primary endpoint).

Secondary endpoints include a subgroup analysis of overall survival in patients who are
positive for a prospectively defined primary biomarker signature (identified as being
predictive for improved clinical outcome in IMA901-vaccinated patients in the previous phase
II study), progression-free survival (PFS), best overall response, cellular immunomonitoring
in a subset of patients, and safety. Safety analysis will be based on adverse events (AEs),
physical examinations, vital signs, hematology, clinical chemistry, urinalysis and ECG
changes.

Further endpoints include subgroup analyses of overall survival in patients who are positive
for further prospectively defined biomarkers (identified in the previous phase II study),
and exploratory screening of new biomarkers (to be investigated in patients' blood and
paraffin sections from tumor tissue) to predict better clinical outcome as response to
vaccination with IMA901. Biomarker sets will not be used for patient selection in this
study.

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00004109
  •   2013/06/06
  •   2010/12/22
  •   no
  •   [---]*
  •   [---]*
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   2010-022459-45 
  •   NCT01265901  (ClinicalTrials.gov)
  •   IMA901-301  (immatics Biotechnologies GmbH)
  •   2010-022459-45 
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   Metastatic Renal Cell Carcinoma
  •   C64 -  Malignant neoplasm of kidney, except renal pelvis
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Drug: Sunitinib
  •   Biological: IMA901 plus GM-CSF
  •   Drug: Cyclophosphamide
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Interventional
  •   [---]*
  •   Randomized controlled trial
  •   Open (masking not used)
  •   [---]*
  •   Active control (effective treament of control group)
  •   Treatment
  •   Parallel
  •   III
  •   [---]*
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

- Overall survival; time frame: 2015 (estimated)

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

- Overall survival in biomarker-defined subgroup; time frame: 2015 (estimated)
- Progression-free survival; time frame: 2014 (estimated)
- Best tumor response; time frame: 2014 (estimated)
- Safety and tolerability; time frame: continuously
- Cellular immunomonitoring; time frame: 2014 (estimated)

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   United States
  •   France
  •   Germany
  •   Hungary
  •   Italy
  •   Netherlands
  •   Norway
  •   Poland
  •   Romania
  •   Russian Federation
  •   United Kingdom
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   [---]*
  •   2010/12/31
  •   330
  •   Multicenter trial
  •   International
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

1. Aged at least 18 years.

2. HLA type: HLA-A*02-positive

3. Metastatic and/or locally advanced RCC with clear cell histology (histological
confirmation by local pathologist required). NOTE: prior nephrectomy is NOT required.

4. Measurable and/or non-measurable tumor lesions as per RECIST 1.1

5. Patients who are candidates for a first-line therapy with sunitinib.

6. Favorable or intermediate risk according to the 6-score risk criteria in patients
treated with VEGF-targeted agents according to Heng [Heng et al. 2009]. The patient
has a favorable risk if none, or intermediate risk if one or two of the following
criteria apply (if three or more criteria apply the patient is not eligible):

1. Hemoglobin < LLN,

2. Serum corrected calcium > ULN,

3. Karnofsky performance status < 80%,

4. Time from initial diagnosis to initiation of therapy < 1 year,

5. Absolute neutrophil count > ULN,

6. Platelets > ULN.

7. Able to understand the nature of the study and give written informed consent.

8. Willingness and ability to comply with the study protocol for the duration of the
study.

9. Female patients who are post menopausal (no menstrual period for a minimum of 1
year), or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or
hysterectomy) or practice a medically acceptable method of birth control.

10. Male patients willing to use contraception (upon study entry and during the course of
the study or have undergone vasectomy.

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

1. Prior systemic therapy for metastatic disease. (Note: prior adjuvant treatment for
non-metastatic disease is allowed, however adjuvant therapy must have been stopped ≥
1 year before Visit C).

2. History of or current brain metastases.

3. Abnormal ≥ CTC Grade 3 laboratory values for hematology (Hb, WBC, neutrophils,
lymphocytes, platelets), liver (serum bilirubin, ALAT or ASAT) and renal function
(serum creatinine).

4. Metastatic second malignancy.

5. Localized second malignancy expected to influence the patient's life span.

6. Patients with a history or evidence of systemic autoimmune disease, e.g., rheumatoid
arthritis, multiple sclerosis, systemic lupus erythematodes (SLE), scleroderma,
Sjögren's syndrome, Wegener's granulomatosis, Guillain-Barre syndrome.

7. Known active hepatitis B or C infection.

8. Known HIV infection.

9. Active infections requiring oral or intravenous antibiotics.

10. Any other known infection with a biological agent that can cause a severe disease and
poses a severe danger to lab personnel working on patients' blood or tissue.

11. Received study drug within any clinical study (including approved and experimental
drugs) within 4 weeks before sunitinib start.

12. Serious intercurrent illness, which according to the investigator, poses an undue
risk for the patient when participating in the trial, including, but not limited to,
any of the following:

- Clinically significant cardiovascular disease (e.g., uncontrolled hypertension;
clinically significant cardiac arrhythmia, clinically significant
QT-prolongation),

- New York Heart Association class III-IV congestive heart failure,

- Symptomatic peripheral vascular disease,

- Severe pulmonary dysfunction,

- Psychiatric illness or social situation that would preclude study compliance.

13. Less than 12 months since any of the following:

- Myocardial infarction,

- Severe or unstable angina,

- Coronary or peripheral artery bypass graft,

- Cerebrovascular event incl. transient ischemic attack,

- Pulmonary embolism / deep vein thrombosis (DVT).

14. Pregnancy or breastfeeding.

15. Any condition which in the judgment of the investigator would place the patient at
undue risk or interfere with the results of the study.

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • immatics Biotechnologies GmbH
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Cleveland Clinic Taussig Cancer Institute
    • Brian Rini, MD 
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Cleveland Clinic Taussig Cancer Institute
    • Brian Rini, MD 
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting complete, follow-up complete
  •   2015/07/01
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
The parameters in ClinicalTrials.gov and DRKS are not identical. Therefore the data import from ClinicalTrials.gov required adjustments. For full details please see the DRKS FAQs .
  •   7
  •   2016/01/14


* This entry means the parameter is not applicable or has not been set.